(Q37960526)

26 August 2017

title

Adverse effects in women: implications for drug development and regulatory policies (English)

1 reference

26 August 2017

Ameeta Parekh

1

1 reference

26 August 2017

Emmanuel O Fadiran

series ordinal

2

1 reference

26 August 2017

Kathleen Uhl

series ordinal

3

1 reference

26 August 2017

Douglas C Throckmorton

series ordinal

4

1 reference

26 August 2017

language of work or name

English

0 references

publication date

1 July 2011

1 reference

Expert Review of Clinical Pharmacology

26 August 2017

published in

1 reference

26 August 2017

volume

4

1 reference

26 August 2017

issue

4

1 reference

26 August 2017

page(s)

453-466

1 reference

Historical background of changes in FDA policy on the study and evaluation of drugs in women

26 August 2017

cites work

1 reference

The role of the NIH's Office of Research on Women's Health

21 January 2018

1 reference

Historical background of clinical trials involving women and minorities

21 January 2018

1 reference

Sex differences in pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

The current state of knowledge on age, sex, and their interactions on clinical pharmacology

21 January 2018

1 reference

Sex differences in pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics

21 January 2018

1 reference

Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome

21 January 2018

1 reference

Dofetilide: a new class III antiarrhythmic agent

21 January 2018

1 reference

A pharmacokinetic-pharmacodynamic model of d-sotalol Q-Tc prolongation during intravenous administration to healthy subjects

21 January 2018

1 reference

Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol.

21 January 2018

1 reference

Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart.

21 January 2018

1 reference

Drug-induced QT prolongation in women during the menstrual cycle

21 January 2018

1 reference

Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes.

21 January 2018

1 reference

Clinical benefit of glycoprotein IIb/IIIa blockade with abciximab is independent of gender

21 January 2018

1 reference

Phenylpropanolamine and the risk of hemorrhagic stroke

21 January 2018

1 reference

Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).

21 January 2018

1 reference

Diabetes drug pioglitazone (Actos): risk of fracture

21 January 2018

1 reference

Participation of women in clinical trials for new drugs approved by the food and drug administration in 2000-2002.

21 January 2018

1 reference

Increasing participation of women in early phase clinical trials approved by the FDA.

21 January 2018

1 reference

The FDA critical path initiative and its influence on new drug development.

21 January 2018

1 reference

Perspectives on early communication of drug risks to the public

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ECP.11.29

1 reference

release_bqqt64xd4bcrvdrha6dsx3dl3e

26 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/bqqt64xd4bcrvdrha6dsx3dl3e

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference